AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
294.50B
Market cap294.50B
Price-Earnings ratio
28.79
Price-Earnings ratio28.79
Dividend yield
1.66%
Dividend yield1.66%
Average volume
2.00M
Average volume2.00M
High today
$193.65
High today$193.65
Low today
$189.45
Low today$189.45
Open price
$192.29
Open price$192.29
Volume
1.43M
Volume1.43M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$122.48
52 Week low$122.48

Stock Snapshot

With a market cap of 294.5B, AstraZeneca(AZN) trades at $190.71. The stock has a price-to-earnings ratio of 28.79 and currently yields dividends of 1.7%.

On 2026-03-16, AstraZeneca(AZN) stock moved within a range of $189.45 to $193.65. With shares now at $190.71, the stock is trading +0.7% above its intraday low and -1.5% below the session's peak.

Trading volume for AstraZeneca(AZN) stock has reached 1.43M, versus its average volume of 2M.

The stock's 52-week range extends from a low of $122.48 to a high of $212.71.

The stock's 52-week range extends from a low of $122.48 to a high of $212.71.

AZN News

Nasdaq 2d
Astrazeneca Dips More Than Broader Market: What You Should Know

Astrazeneca (AZN) closed the most recent trading day at $189.90, moving -1.35% from the previous trading session. The stock's performance was behind the S&P 500...

Astrazeneca Dips More Than Broader Market: What You Should Know
TipRanks 3d
AstraZeneca’s Lynparza Safety Study in Japan: What the Latest Update Signals for AZN Investors

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The study LYNPARZA Tablets 100mg, 150mg General Drug Use-results Study tracks how Astr...

TipRanks 4d
AstraZeneca’s DURGA-4 CAR-T Study Puts New Pressure on Multiple Myeloma Rivals

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. The DURGA-4 study, formally titled “A Phase III Open-label, Randomised, Multicent...

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
12.9%
Sell
6.5%

More AZN News

TipRanks 4d
AstraZeneca Advances Pediatric Symbicort Device Study, Supporting Long Term Respiratory Strategy

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca study tracks how two versions of its asthma drug move through childre...

Benzinga 4d
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline

British drugmaker AstraZeneca Plc (NYSE:AZN) has emerged as the leading contender to acquire French biotech Abivax SA (NASDAQ:ABVX) , following the company's dr...

Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
TipRanks 4d
Abivax jumps 15% to $129.11 after report of exclusivity with AstraZeneca

05:45 EDT Abivax (ABVX) jumps 15% to $129.11 after report of exclusivity with AstraZeneca (AZN) Published first on TheFly – the ultimate source for real-time,...

TipRanks 4d
AstraZeneca granted exclusive period by Abivax for buyout, La Lettre reports

Abivax (ABVX) has granted AstraZeneca (AZN) an exclusive period through March 23 to access confidential information and formalize a potential takeover offer, La...

TipRanks 6d
AstraZeneca Wraps Real-World Lung Cancer Study, Sharpening Market Insight for AZN Investors

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The study Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment...

TipRanks 6d
AstraZeneca Completes Key Japan Safety Study for Imfinzi/Imjudo in Liver Cancer

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The study “Specific Use-results Study of IMJUDO Intravenous Infusion 25 mg, 300 mg / I...

TipRanks 6d
AstraZeneca Sets Digitally Enabled 2026 AGM with Key Governance and Capital Votes

The latest update is out from AstraZeneca ( (GB:AZN) ). AstraZeneca has published the notice and shareholders’ circular for its 2026 Annual General Meeting, wh...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.